National Drug Strategy Household Survey, 2022-2023

The 2022–2023 National Drug Strategy Household Survey was conducted in two phases, the first between July and December of 2022 and the second between March and May 2023. The survey examines current awareness of attitudes and behaviours toward drugs and drug problems within the Australian community, focusing on respondents' personal attitudes toward drugs, knowledge of drugs and drug histories. </br></br>

The survey included questions regarding respondents' personal drug and alcohol experience and behaviour, opinions on drug policy and legislation, availability of drugs and alcohol, injury and harm from drugs and alcohol, and attitudes towards the use of alcohol and other drugs. The drugs covered included: tobacco/cigarettes, e-cigarettes/vapes, alcohol, kava, pain-killers/pain-relievers and opioids, tranquillisers, heroin, methadone, inhalants, ketamine, GHB, ecstasy, hallucinogens, cocaine, methamphetamine and amphetamine, pharmaceutical stimulants, cannabis/marijuana, synthetic cannabis, other psychoactive substances, and steroids. Demographic and background variables included: state of residence, age, gender, marital status, self-assessed health status, sexuality, Indigenous status, country of birth, language spoken at home, employment status, occupation, level of education, income, index of socio-economic advantage and disadvantage, remoteness area and household composition.